KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Assets Average (2021 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Assets Average for 5 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 32.12% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Dec 2025, up 32.12%, and an annual FY2025 reading of $1.5 billion, up 39.03% over the prior year.
  • Assets Average was $1.4 billion for Q4 2025 at Recursion Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.4 billion in Q4 2025 and bottomed at $285.3 million in Q1 2021.
  • Average Assets Average over 5 years is $797.0 million, with a median of $665.6 million recorded in 2023.
  • The sharpest move saw Assets Average soared 135.69% in 2022, then dropped 8.81% in 2024.
  • Year by year, Assets Average stood at $634.5 million in 2021, then increased by 3.46% to $656.4 million in 2022, then decreased by 2.16% to $642.3 million in 2023, then surged by 69.33% to $1.1 billion in 2024, then soared by 32.12% to $1.4 billion in 2025.
  • Business Quant data shows Assets Average for RXRX at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.